TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16980161

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 30
Study: 12745490

Group type: EXPERIMENTAL
Intervention: Nicotine patch alone
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray alone
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Combination therapy (nicotine patch + nicotine nasal spray)
Number of subjects: 1384

Group type: COMPARATOR
Intervention: Nicotine patch alone, Nicotine nasal spray alone, Combination therapy
Number of subjects: 1384
Study: 10774967

Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy
Number of subjects: 53
Study: 8627439

Group type: EXPERIMENTAL
Intervention: Preservative-free topical ointment therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no topical treatment or as-needed therapy with a water-in-oil emollient)
Number of subjects: 60
Study: 7969210

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 57

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 57
Study: 2887101

Group type: COMPARATOR
Intervention: Propranolol (0.1 mg/kg intravenously)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Metoprolol (0.15 mg/kg intravenously)
Number of subjects: 23
Study: 29316164

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly plus dapagliflozin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study: 27391640

Group type: EXPERIMENTAL
Intervention: Once-daily 5% minoxidil topical foam (MTF)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Twice-daily 2% minoxidil topical solution (MTS)
Number of subjects: 322
Study: 25622626

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 112

Group type: COMPARATOR
Intervention: CNI
Number of subjects: 112
Study: 24641892

Group type: EXPERIMENTAL
Intervention: DepoDur (extended-release epidural morphine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Duramorph (control)
Number of subjects: 60
Study: 23310938

Group type: EXPERIMENTAL
Intervention: 1 mg/kg propofol (PG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5 mg/kg thiopentone (TG)
Number of subjects: 40
Study: 20083683

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 341

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 341
Study: 18049395

Group type: EXPERIMENTAL
Intervention: Needlescopic cholecystectomy (NC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Needlescope-assisted cholecystectomy (NAC)
Number of subjects: 40
Study: 16042640

Group type: EXPERIMENTAL
Intervention: Slow-release morphine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 64
Study: 11826587

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 0
Study: 10207709

Group type: EXPERIMENTAL
Intervention: Couple-responsible episodes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Therapist-responsible episodes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Contrast condition (previous therapist process)
Number of subjects: 25
Study: 8801446

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg per day
Number of subjects: 4159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study: 1592970

Group type: EXPERIMENTAL
Intervention: Dentifrice with 1000 micrograms F/g
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dentifrice with 1500 micrograms F/g
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dentifrice with 2500 micrograms F/g
Number of subjects: 7

Group type: COMPARATOR
Intervention: Dentifrice with 0 micrograms F/g (control)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fluoride-containing dentifrices (1000, 1500, 2500 micrograms F/g)
Number of subjects: 7
Study: 6329092

Group type: EXPERIMENTAL
Intervention: pivmecillinam 400 mg every 6 h for 5 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: ampicillin 500 mg every 6 h for 5 days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: pivmecillinam 400 mg every 6 h for 5 days (excluding resistant strains)
Number of subjects: 44

Group type: COMPARATOR
Intervention: ampicillin 500 mg every 6 h for 5 days (excluding resistant strains)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: pivmecillinam 400 mg every 6 h for 5 days (susceptible strains)
Number of subjects: 44

Group type: COMPARATOR
Intervention: ampicillin 500 mg every 6 h for 5 days (susceptible strains)
Number of subjects: 44
Study: 30799839

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment coupled with lactation consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29399843

Group type: EXPERIMENTAL
Intervention: High Desisting Aggression group
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: High Study Skills group
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Overall dropout rate
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Stable trajectories of study skills
Number of subjects: 620
Study: 26964911

Group type: EXPERIMENTAL
Intervention: Wet lab training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Virtual reality lab training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dry lab training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Virtual reality simulation training
Number of subjects: 40
Study: 25864252

Group type: EXPERIMENTAL
Intervention: Abdominopelvic binder
Number of subjects: 75
Study: 22244049

Group type: EXPERIMENTAL
Intervention: Iferanserin 10 mg BID
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 20446586

Group type: EXPERIMENTAL
Intervention: Voglibose 0.2 mg three times a day
Number of subjects: 1780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1780
Study: 17668978

Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1% CHX
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 40% CHX
Number of subjects: 33

Group type: COMPARATOR
Intervention: Professional tooth cleaning
Number of subjects: 33
Study: 15672372

Group type: EXPERIMENTAL
Intervention: Mobile phone switched on
Number of subjects: 55

Group type: COMPARATOR
Intervention: Mobile phone switched off
Number of subjects: 55
Study: 11958305

Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion with dextrose 5%‐based cardioplegic solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sliding scale insulin treatment with normal saline 0.9%‐based cardioplegic solution
Number of subjects: 50
Study: 10448871

Group type: COMPARATOR
Intervention: Tumor rCBF and rCBV
Number of subjects: 5

Group type: COMPARATOR
Intervention: rCMRO2 and rOEF
Number of subjects: 5

Group type: COMPARATOR
Intervention: Kinetic tumor rCMRGl
Number of subjects: 5

Group type: COMPARATOR
Intervention: Autoradiographic tumor rCMRGl
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: K3 and kinetic rCMRGl of the recurring tumor
Number of subjects: 5

Group type: COMPARATOR
Intervention: Postoperative follow-up
Number of subjects: 5
Study: 7499664

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate pre-rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Essential oils pre-rinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water pre-rinse
Number of subjects: 0
Study: 1430701

Group type: EXPERIMENTAL
Intervention: Budesonide (0.4 mg at 8 AM and 8 PM)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bambuterol (20 mg at 8 PM)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6744406

Group type: EXPERIMENTAL
Intervention: Brachial approach (antecubital cutdown procedure)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Femoral approach (percutaneous)
Number of subjects: 56
Study: 30720538

Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stem/stromal cells (0.3, 1.0, or 3.0 million cells/kg body weight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no mesenchymal stem/stromal cells)
Number of subjects: 30
Study: 30189251

Group type: EXPERIMENTAL
Intervention: Topical postoperative tobramycin-dexamethasone
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 70
Study: 26659113

Group type: EXPERIMENTAL
Intervention: Expressive writing (n=33)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Treatment-as-usual (control group, n=32)
Number of subjects: 67
Study: 24781441

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (405 mg/4 weeks)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Oral olanzapine (10 mg/d)
Number of subjects: 524
Study: 22613240

Group type: EXPERIMENTAL
Intervention: Circuit class therapy with heart rate monitor feedback
Number of subjects: 53

Group type: COMPARATOR
Intervention: Circuit class therapy without heart rate monitor feedback (Control)
Number of subjects: 53
Study: 20053720

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 210

Group type: COMPARATOR
Intervention: Back school
Number of subjects: 210

Group type: COMPARATOR
Intervention: Individual physiotherapy
Number of subjects: 210
Study: 17349034

Group type: EXPERIMENTAL
Intervention: Oral treatment for community acquired pneumonia
Number of subjects: 243

Group type: COMPARATOR
Intervention: Intravenous (IV) treatment for community acquired pneumonia
Number of subjects: 243
Study: 15549302

Group type: EXPERIMENTAL
Intervention: CH-SS-impregnated central venous catheters (CVCs) (n=51)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard uncoated triple-lumen CVC (Control) (n=55)
Number of subjects: 106
Study: 11966418

Group type: EXPERIMENTAL
Intervention: Individual, family, and community resources
Number of subjects: 261
Study: 10202364

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated allergic children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 0
Study: 7596624

Group type: EXPERIMENTAL
Intervention: 100 mg imipramine
Number of subjects: 12
Study: 2161692

Group type: EXPERIMENTAL
Intervention: hPTH 1‐38 (400 IU/day subcutaneous injection)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: hPTH 1‐38 (0.5 U/kg/h intravenous infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: hPTH 1‐38 (intermittent treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: hPTH 1‐38 therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: hPTH 1‐38 treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Calcitonin (100 U/day for 56 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 20
Study: 105096

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31522133

Group type: EXPERIMENTAL
Intervention: Cigarette and e-cigarette dual-use
Number of subjects: 601

Group type: COMPARATOR
Intervention: Cigarette-only smoking
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Cigarette and cannabis dual-use
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Cigarette and e-cigarette use
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Cigarette, e-cigarette, and cannabis poly-use
Number of subjects: 601
Study: 27834959

Group type: EXPERIMENTAL
Intervention: Pterygium tissues
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal conjunctival tissues
Number of subjects: 25
Study: 24806469

Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCTs) intervention
Number of subjects: 239
Study: 23889806

Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21827773

Group type: EXPERIMENTAL
Intervention: Gallic acid (GA) supplementation (12.8 mg/person/d) for three days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gallic acid (GA) in rats
Number of subjects: 0
Study: 19800668

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 16954767

Group type: EXPERIMENTAL
Intervention: One-hour nursing rounds
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Two-hour nursing rounds
Number of subjects: 27

Group type: COMPARATOR
Intervention: Baseline data (no intervention)
Number of subjects: 27
Study: 14709514

Group type: EXPERIMENTAL
Intervention: Different facemasks used for aerosol medication delivery
Number of subjects: 0
Study: 11830774

Group type: EXPERIMENTAL
Intervention: Neuroendoscopic operations (n = 10)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional cystoperitoneal shunting operations (n = 28)
Number of subjects: 38
Study: 9228352

Group type: EXPERIMENTAL
Intervention: Albuterol solution, 5 mg via nebulizer (Puritan‐Bennett Raindrop) impelled with oxygen at 8 L/min
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Albuterol, 400 microg via CFCMDI attached to a 145‐mL valved aerosol holding chamber (Aerochamber)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Albuterol powder, 400 microg by Rotahaler
Number of subjects: 27
Study: 8028563

Group type: EXPERIMENTAL
Intervention: embovin (10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: combatrin (10 mg/kg)
Number of subjects: 0
Study: 2960867

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 26
Study: 29475446

Group type: EXPERIMENTAL
Intervention: Fish meals
Number of subjects: 415

Group type: COMPARATOR
Intervention: Meat meals
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA supplements
Number of subjects: 415
Study: 27456448

Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy (three times daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care physiotherapy (daily)
Number of subjects: 92
Study: 25573904

Group type: EXPERIMENTAL
Intervention: Ritonavir powder formulation in water under fasting, moderate-fat or high-fat conditions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ritonavir powder formulation in chocolate milk or pudding under moderate-fat conditions
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ritonavir oral solution under moderate-fat conditions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ritonavir powder formulation in infant formula or apple sauce under moderate-fat conditions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Moderate-fat meals
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High-fat meals
Number of subjects: 72
Study: 23964054

Group type: EXPERIMENTAL
Intervention: High-SFA (HS) diet
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: High-MUFA (HM) diet
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) diet
Number of subjects: 121
Study: 20044759

Group type: EXPERIMENTAL
Intervention: Auditory discrimination training (ADT) in the same frequency of tinnitus pitch (SAME)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Auditory discrimination training (ADT) in the frequency one-octave below tinnitus pitch (NONSAME)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (waiting list group, WLG)
Number of subjects: 67
Study: 18671882

Group type: EXPERIMENTAL
Intervention: Puzzle form of the Raven's Coloured Progressive Matrices (RCPM)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Book form of the Raven's Coloured Progressive Matrices (RCPM)
Number of subjects: 164
Study: 16248249

Group type: EXPERIMENTAL
Intervention: Integrative traditional and Western medicine (conventional Western medicine combined with Chinese compound recipe)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional Western medicine alone
Number of subjects: 72
Study: 14504325

Group type: EXPERIMENTAL
Intervention: Retinopathy
Number of subjects: 1684

Group type: COMPARATOR
Intervention: Other retinal arteriolar characteristics (arteriovenous nicking, focal and generalized arteriolar narrowing)
Number of subjects: 1684
Study: 9862837

Group type: EXPERIMENTAL
Intervention: Magnetic resonance cholangiography (MRC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Reference imaging methods (endoscopic retrograde cholangiography, endosonography, intraoperative cholangiography)
Number of subjects: 70
Study: 9715310

Group type: EXPERIMENTAL
Intervention: Picrorhiza kurroa (Pk) root powder 375 mg three times a day for 2 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 2067712

Group type: EXPERIMENTAL
Intervention: Sulbactam/Ampicillin (S/A)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Mezlocillin (M)
Number of subjects: 65
Study: 6828609

Group type: EXPERIMENTAL
Intervention: Low dose of caffeine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Medium dose of caffeine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High dose of caffeine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 30994935

Group type: EXPERIMENTAL
Intervention: 25 mM acetic acid in 0.1 M CaCl2 brines
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hydrochloric acid in 0.1 M CaCl2 brines
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.1 M CaCl2 brines (without acidification)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 1 M NaCl brines
Number of subjects: 6
Study: 28243598

Group type: COMPARATOR
Intervention: CT scans
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RSA double examinations
Number of subjects: 46
Study: 25719441

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Omeprazole with Rosuvastatin
Number of subjects: 20
Study: 24615500

Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) 10 mg/day + Exemestane (EXE) 25 mg/day
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo (PBO) + Exemestane (EXE) 25 mg/day
Number of subjects: 724
Study: 22433267

Group type: EXPERIMENTAL
Intervention: Morning training group (MTG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Evening training group (ETG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups (T0)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups (T1)
Number of subjects: 24
Study: 19670432

Group type: EXPERIMENTAL
Intervention: microS (MRX‐801) infusion over 90 minutes (Cohort 1, 1.4ml)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: microS (MRX‐801) infusion over 90 minutes (Cohort 2, 2.8ml)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: microS (MRX‐801) infusion over 90 minutes (Cohort 1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: microS (MRX‐801) infusion over 90 minutes (Cohort 2)
Number of subjects: 35

Group type: COMPARATOR
Intervention: tPA and brief TCD assessments (controls)
Number of subjects: 35
Study: 18467522

Group type: EXPERIMENTAL
Intervention: Unblinded group (MR imaging results provided within 48 hours)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Blinded group (both patient and physician blinded to MR imaging results)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Blinded group
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Unblinded group
Number of subjects: 246
Study: 16140896

Group type: EXPERIMENTAL
Intervention: 1 mg riboflavin + 20 mg iron (n = 83)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: 20 mg zinc (n = 83)
Number of subjects: 333

Group type: COMPARATOR
Intervention: 1 mg riboflavin (control, n = 82)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: both (n = 85)
Number of subjects: 333
Study: 12151469

Group type: EXPERIMENTAL
Intervention: iloprost (2.5 or 5.0 microg, six or nine times per day; median inhaled dose, 30 microg per day)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: iloprost
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: iloprost (subgroup of primary pulmonary hypertension)
Number of subjects: 203

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 203
Study: 9935128

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 100 mg/d orally on days 1-10 of the menstrual cycle
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg orally twice daily
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Triptorelin 3.75 mg IM every 28 days
Number of subjects: 39
Study: 7486235

Group type: EXPERIMENTAL
Intervention: E5510 4 mg
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: E5510 2 mg
Number of subjects: 227

Group type: COMPARATOR
Intervention: Aspirin 324 mg
Number of subjects: 227
Study: 2248075

Group type: EXPERIMENTAL
Intervention: Moclobemide (150-300 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tranylcypromine (15-30 mg daily)
Number of subjects: 20
Study: 7377243

Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 208

Group type: COMPARATOR
Intervention: Elective cesarean section
Number of subjects: 208
Study: 31365903

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 620
Study: 27761984

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 25399316

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (250 mg capsules every 8 h)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Ginger (250 mg capsules every 6 h)
Number of subjects: 122
Study: 24512486

Group type: EXPERIMENTAL
Intervention: Octreotide 100 μg sc
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (before administration of octreotide)
Number of subjects: 10
Study: 20924555

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 1218
Study: 19346521

Group type: EXPERIMENTAL
Intervention: Candesartan-based therapy
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Non-ARB-based pharmacotherapy
Number of subjects: 2049
Study: 17277998

Group type: EXPERIMENTAL
Intervention: Aspirin (81-325 mg daily for at least a week)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily for at least 3 days)
Number of subjects: 100
Study: 15531660

Group type: EXPERIMENTAL
Intervention: PUFA-rich diet (P:S = 2.0)
Number of subjects: 16

Group type: COMPARATOR
Intervention: SFA-rich diet (P:S = 0.25)
Number of subjects: 16